More on Arena Pharmaceuticals (ARNA): Q3 beats on a per share basis but comes up short on...

More on Arena Pharmaceuticals (NASDAQ:ARNA): Q3 beats on a per share basis but comes up short on revenue. Separately, the company announced that it had granted Ildong Pharmaceutical exclusive rights to market and distribute its weight-loss drug Belviq in South Korea, subject to regulatory approval of BELVIQ by the Korea Food and Drug Administration. Shares +1.6% AH.

From other sites
Comments (8)
  • Iqbal1
    , contributor
    Comments (54) | Send Message
    seems to be winner in the long terms.


    Have a nice day for all investors.
    6 Nov 2012, 04:44 PM Reply Like
  • mikes454
    , contributor
    Comments (11) | Send Message
    If you ever buy a stock in your entire life this is the one! I have been a trader for over 40 years and missed many opportunities as well as made some modest gains, however this is the most reasonable safe investment you can make and you could make a substantial profit.
    6 Nov 2012, 05:47 PM Reply Like
  • plhovsepian
    , contributor
    Comments (7) | Send Message
    Doctors need tools to help their patients who deal with the disease of OBESITY. Belviq is ONE of those tools. Come one FDA/DEA lets get that sucker approved so people can get help.


    6 Nov 2012, 05:52 PM Reply Like
  • gregptpt
    , contributor
    Comments (71) | Send Message
    I couldn't access the CC. Was anything concrete mentioned about the FDA/ DEA issue which is the one true piece people both long and short all really want to hear?
    6 Nov 2012, 07:11 PM Reply Like
  • mileway
    , contributor
    Comments (5) | Send Message
    I see ARNA at $20 in a year at most
    7 Nov 2012, 12:24 AM Reply Like
  • busterpanda
    , contributor
    Comments (82) | Send Message
    Technicals look good, stochastics are way oversold. The price is bouncing off august support level of 7.40. Good news and this stock will take off again for another run at $10.
    7 Nov 2012, 06:19 AM Reply Like
  • Robert J. Yale
    , contributor
    Comments (301) | Send Message
    "Comes up short on revenue ?" Come on sales YET !!!
    Let's dig a little bit deeper into the cc of Nov.6 please.
    7 Nov 2012, 08:42 AM Reply Like
  • feather
    , contributor
    Comment (1) | Send Message
    I have a little knowledge about the market. I have been with MM for the past 8 to 10 years, going thru the trials of some stocks that are still eye sores. Knowing that the stupid bug got me in RE:Diamond Fields. Another of the would A shoulda stocks. I watched the ship leave the shore and waved bye bye to a lot of money. Thanks for ARENA. Now I hope I will be able to get back in at a good price.
    I was able to recoup a lot. I have been disabled for the past 20 years so I have to push the pain aside with medication, but It is a Long time squatter that will never leave.
    7 Nov 2012, 03:06 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs